MDRNA and AstraZeneca China Collaborating on Cancer

MDRNA, Inc. announced an RNAi cancer collaboration with AstraZeneca Investment (China) Company that is being carried out at AstraZeneca’s Innovation Center in Shanghai. MDRNA’s RNA interference technology combines two proteins to inhibit two processes. In the AstraZeneca collaboration, the formulation is being tested as a treatment for liver cancer. More details... Stock Symbol: (NSDQ: MRNA)